SIGA Overview

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.

Wall Street analysts forecast SIGA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SIGA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

SIGA Technologies Inc revenue for the last quarter amounts to -79.31M USD, decreased -197.35

SIGA Technologies Inc. EPS for the last quarter amounts to -0.08 USD, decreased -112.50

SIGA Technologies Inc (SIGA) has 46 emplpoyees as of March 11 2026.

Today SIGA has the market capitalization of 404.60M USD.